Biocon Biologics is focused on improving cash flows and increasing market shares of its biosimilar products, particularly in the US and Eur...

Biocon Biologics on Thursday said it has completed the integration of the acquired biosimilar business from Viatris Inc in 31 European coun...

"The USFDA has issued a CRL for the Biologics License Application (BLA) for Bevacizumab filed by our partner Viatris (Mylan)," a company sp...

Biocon’s share price climbed to a high of Rs 334.70 as against Rs 322.95 at previous close on the BSE.Abevmy is a recombinant humanized mon...

Abevmy is approved for treatment in metastatic colorectal carcinoma, metastatic breast cancer, non small-cell lung carcinoma, glioblastoma,...

Abevmy is abiosimilar to Roche's Avastin, prescribed for all indications including metastatic colorectal carcinoma, metastatic breast cance...

"To complete the application, the agency noted that an inspection of the manufacturing facility is required as a part of the standard revie...

Biocon and Mylan’s proposed biosimilar bevacizumab, a cancer drug, is expected to be the third biosimilar from the partnered portfolio for ...

Biosimilars are approved versions of biopharmaceuticals — complex medicines manufactured using live organisms, as against conventional drug...

Under the terms of the agreement, both companies will share responsibility for end to end development, manufacturing and global regulatory ...

A biosimilar is a near copy of an original complex biologic drug.

The biosimilar product will be used for the treatment of patients with metastatic colorectal cancer and other types of lung, kidney, cervic...

Biosimilar drugs are the follow on versions of biologic drugs which are composed of sugars, proteins, nucleic acids or complex combinations...

The company had posted a net profit of Rs 166.6 crore for the corresponding quarter of the previous fiscal, Biocon said in a BSE filing.

In 2014, Reliance had entered into a similar arrangement with Torrent Pharma to sell copies of three drugs -- rituximab, adalimumab and cet...

Roche, which invented the drug and markets it under the blockbuster brand ‘Avastin’, has argued that Hetero’s drug is not a biosimilar to b...

The judge asked the company to submit a compilation of judgments highlighting the protection given to drug innovators to support its call.